Association of Polymorphisms in the Glutathione S-Transferase Theta-1 Gene with Cirrhosis and Hepatocellular Carcinoma in Brazilian Patients with Chronic Hepatitis C

Oxidative stress contributes to hepatitis C virus (HCV)–induced liver damage. Host genetic factors may be involved in progression of HCV infection. The present study was conducted to determine the influence of glutathione S-transferase (GST)-M1 and T1 gene polymorphisms during different stages of HC...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-07, Vol.9 (8), p.831
Main Authors: Araujo, Oscar C., de Paula, Vanessa S., do Ó, Kycia M., Villela-Nogueira, Cristiane A., Araujo, Natalia M.
Format: Article
Language:English
Subjects:
Biomarkers
Chronic infection
Cirrhosis
Communication
Confidence intervals
Etiology
Gene polymorphism
Genes
Genetic factors
Genotype & phenotype
Genotypes
Glutathione
glutathione S-transferases
Glutathione transferase
GSTM1 protein
GSTT1 gene
GSTT1 protein
Hepatitis
Hepatitis C
hepatitis C virus
Hepatocellular carcinoma
Infections
Laboratories
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Oxidative stress
Polymerase chain reaction
polymorphisms
Population studies
Statistical analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxidative stress contributes to hepatitis C virus (HCV)–induced liver damage. Host genetic factors may be involved in progression of HCV infection. The present study was conducted to determine the influence of glutathione S-transferase (GST)-M1 and T1 gene polymorphisms during different stages of HCV infection, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The study population comprised 190 patients (47 with chronic hepatitis, 83 with cirrhosis (without HCC), and 60 with HCC). GSTM1 and GSTT1 gene polymorphisms were analyzed via multiplex polymerase chain reaction. The GSTT1-null genotype was more commonly detected in patients with cirrhosis (n = 17; 20.5%) and HCC (n = 13; 21.7%) than those with chronic hepatitis (n = 3; 6.4%). The differences in GSTT1-null genotype frequencies were significant for cirrhosis vs. chronic hepatitis (odds ratio, OR, 3.778 (95% confidence interval, CI, 1.045–13.659); p = 0.043) and HCC vs. chronic hepatitis (OR, 4.057 (95% CI, 1.083–15.201); p = 0.038) groups. However, the incidence of individual GSTM1-null or combined GSTM1/GSTT1 double-null genotypes did not vary significantly between the groups. Our collective findings support the utility of the GSTT1-null genotype as a useful biomarker for liver disease progression in Brazilian patients with chronic hepatitis C.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9080831